- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00130949
ALGRX 4975 in the Treatment of Tennis Elbow
A Randomized, Double-Blind, Placebo-Controlled, Phase II, Exploratory Evaluation of ALGRX 4975 in Subjects With Acute Lateral Epicondylitis
Study Overview
Detailed Description
Lateral epicondylitis (tennis elbow) is a painful condition that affects 4 to 7 adults per 1000 annually and tends to involve the subject's dominant side. It typically results from repetitive arm movement with over use of muscles leading to small tears in the tendons attaching muscles of the forearm to the epicondyles that may progress to tendonitis. Pain on or around the lateral epicondyle may radiate down the subject's arm. Gripping or extending the wrist often intensifies the pain.
More than 40 possible treatments have been proposed, reflecting a lack of consensus about optimal management. Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used to treat tennis elbow, but there are no trials to date that have compared them with other painkillers and one study found no clinically important benefit over placebo. Use of corticosteroid injections provides mixed results in relief of pain and at times insufficient evidence to support their use. Although complications associated with steroid injection are relatively uncommon, when a complication does occur, it can result in severe and disabling consequences for the subject. A small proportion of subjects fail to respond to only one injection of corticosteroid and some subjects who initially improved at four weeks had worse symptoms by six months.
This study has been designed to evaluate the safety and efficacy of a single soft tissue injection of ALGRX 4975 at a dose of 100 µg in comparison to placebo in subjects with acute LE.
Study Type
Enrollment
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Kosice, Slovakia, 040 11
- Ortopedicko-Traumatologicka Klinika
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Acute lateral epicondylitis (LE) of less than 3 months duration (subjects with recurrent acute LE may be included).
- A screening and baseline severity of pain on resisted wrist dorsiflexion score of moderate or greater intensity.
- Lidocaine responsive.
- A systolic and diastolic blood pressure not greater than 140 and 95 mm Hg, respectively.
Exclusion Criteria:
- Any clinically significant form of joint disease, elbow trauma or neuromuscular disorder at the elbow, other than acute LE.
- Physiotherapy treatment within the preceding 2 weeks, prior to Visit 1.
- Any systemic or local corticosteroids within the preceding 3 months, except nasal or inhaled steroids at less than or equal to 1000 mcg/day.
- A medical condition other than LE that requires the use of a pain medication.
- A peripheral sensory or motor neuropathy involving the upper extremities.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Pain induced by resisted wrist dorsiflexion 4 weeks after treatment
|
Secondary Outcome Measures
Outcome Measure |
---|
Grip strength
|
Pain induced by resisted wrist dorsiflexion (other than 4 weeks)
|
Pain experienced during the grip strength test
|
Pain in elbow over previous 24 hours
|
Effect on work
|
Tenderness elicited by investigator or designee
|
Subjects' global impression of change
|
Secondary outcomes are evaluated at 1, 2, 4, 8 and 12 weeks.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Gabriel Vasko, MD PhD, Ortopedicko-Traumatologicka Klinika, Kosice, Slovak Republic
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 4975-2-005-2
- Eudra CT No : 2004-001000-12
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tennis Elbow
-
Miriam MarksRecruitingElbow Tendinitis | Elbow, TennisSwitzerland
-
Indiana Hand to Shoulder CenterCTM BiomedicalEnrolling by invitationTennis Elbow | Lateral Elbow Tendinopathy | Lateral Epicondylitis \(Tennis Elbow\)United States
-
HydroCision, Inc.CompletedElbow, TennisUnited States
-
Kasiak Research Pvt. Ltd.UnknownLateral Epicondylitis (Tennis Elbow)India
-
Travanti Pharma Inc.Cetero Research, San AntonioUnknownLateral Epicondylitis (Tennis Elbow)United States
-
Kaunas University of MedicineUniversity Hospital, LinkoepingUnknown
-
Haseki Training and Research HospitalCompletedLateral Epicondylitis (Tennis Elbow)Turkey
-
McMaster UniversityArthrex, Inc.; The Physicians' Services Incorporated Foundation; Radiological...TerminatedLateral Epicondylitis (Tennis Elbow)Canada, United States
-
University Hospitals Cleveland Medical CenterWithdrawnLateral Epicondylitis (Tennis Elbow)United States
-
Travanti Pharma Inc.ResearchPointCompletedLateral Epicondylitis | (Tennis Elbow)United States
Clinical Trials on ALGRX 4975
-
AlgoRx PharmaceuticalsCompleted
-
AlgoRx PharmaceuticalsCompletedPostoperative PainFormer Serbia and Montenegro
-
AlgoRx PharmaceuticalsCompletedPostoperative PainDenmark
-
AlgoRx PharmaceuticalsCompletedKnee Injuries | Arthroplasty, Replacement, KneeUnited States
-
Rigshospitalet, DenmarkCompleted
-
AlgoRx PharmaceuticalsCompletedProcedural PainUnited States
-
Anesiva, Inc.CompletedTotal Knee Arthroplasty (Replacement)United States
-
AlgoRx PharmaceuticalsCompleted
-
AlgoRx PharmaceuticalsCompleted
-
Centrexion TherapeuticsCompletedMorton's NeuromaUnited States